|
Prior to joining Progen Dr Laurence Marton was the Chief Scientific Officer of Cellgate and before that Chief Scientific and Medical Officer of SLIL Biomedical Corporation. Both of these companies focused on the discovery and development of novel polyamine analogs and other compounds for the treatment of cancer and other serious diseases. Dr Marton co-founded SLIL and served as a director.
Dr Marton was previously Dean of the University of Wisconsin-Madison Medical School and before that Chaired the department of Laboratory Medicine at the University of California San Francisco. He is a leading expert with extensive experience in the fields of cell growth and drug development. His work is focused on the use of polyamines in treating human diseases related to aberrant cell growth including cancer and infectious diseases. His research has resulted in more than 180 original publications 60 scientific reviews and chapters four books numerous patents and his work has been acknowledged internationally.
Dr Marton serves as a consultant for industry and for governmental and academic institutions. He serves on the Board of the Foundation for Cardiovascular and Transplant Research and was appointed by the Governor of Wisconsin to the Wisconsin Technology Council. Dr Marton received his BA from Yeshiva University and his MD from the Albert Einstein College of Medicine. | 